NfL is a well-studied blood biomarker test that is now widely available through Labcorp for assessing neuronal damage from neurodegenerative diseases and sports-related concussion.
Neurofilament light chain (NfL) is a neuron-specific protein routinely released into the extracellular space. NfL test levels rise above baseline in response to neuronal injury and neurodegeneration. NfL has been widely studied and has demonstrated utility for various neurodegenerative diseases1, including:
NfL has been widely studied as a marker of disease progression, treatment efficacy, and clinical outcomes .1,2
Elevated NfL levels can be a predictor of disease progression in symptomatic patients with subjective cognitive decline .3
NfL levels correlate with disease severity and motor and cognitive decline.4,5
NfL levels can have diagnostic and prognostic value for symptomatic patients6 and distinguish early onset ALS patients from those with other neurologic diseases.7
NfL can help stratify preataxic individuals with regard to onset and facilitate early detection of neurodegeneration.8
NfL can be used in conjunction with clinical observation, as a primary biomarker to assess return to play in concussed athletes.9-11
NfL levels in healthy patients and are known to increase with age.12,13 Labcorp has established reference intervals by age groups to facilitate interpretation of NfL results.
Explore more material on the NfL test, including a technical white paper and a webinar hosted in partnership with Xtalks.
We want to be your partner in neurology, clinically and scientifically.
If you have an idea for a collaborative study, we would be interested in discussing it with you.
Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.
Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.
While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.
The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.